Ac Immune Sa · NASDAQ:ACIU
Ac Immune Sa — Shareholder Meeting (June 2023)
49 slides from Ac Immune Sa's shareholder meeting presentation, Jun 26, 2023
Slide 1: Pioneering Precision Medicine for Neurodegeneration
NASDAQ: ACIU | AGM Presentation, June 2023 © 2023 AC Immune. Not to be used or reproduced without permission Pioneering Precision Medicine for Neurodegeneration NASDAQ: ACIU | Annual General Meeting, June 23, 2023 www.acimmune.com Version: 19.06.2023
Slide 2: Disclaimer
NASDAQ: ACIU | AGM Presentation, June 2023 © 2023 AC Immune. Not to be used or reproduced without permission Disclaimer This presentation contains statements that constitute “forward - looking statements” within the meaning of Section 27 A of the Securities Act of 1933 and Section 21 E of the Securi
Slide 3: Agenda
NASDAQ: ACIU | AGM Presentation, June 2023 © 2023 AC Immune. Not to be used or reproduced without permission 3 Agenda 1. AC Immune’s approach to neurodegenerative diseases 2. Business strategy and pipeline update 3. Clinical - stage vaccine programs 4. Achievements and key milestones 2022/23 5. Fina
Slide 4: AC Immune pioneering new ways to treat neurodegenerative diseases
NASDAQ: ACIU | AGM Presentation, June 2023 © 2023 AC Immune. Not to be used or reproduced without permission AC Immune pioneering new ways to treat neurodegenerative diseases Combining Precision Medicine and early, targeted treatment 4 Broad, diverse pipeline – 16 programs 1 Phase 3 program and 5 in
Slide 5: Neurodegenerative diseases represent a large and growing market
NASDAQ: ACIU | AGM Presentation, June 2023 © 2023 AC Immune. Not to be used or reproduced without permission Neurodegenerative diseases represent a large and growing market Prevention the best avenue to long - term preservation of cognition and function. 5 >$1 Trillion global annual cost of dementia
Slide 6: SupraAntigen and Morphomer platforms
NASDAQ: ACIU | AGM Presentation, June 2023 © 2023 AC Immune. Not to be used or reproduced without permission SupraAntigen ® and Morphomer ® platforms An integrated approach to Central Nervous System (CNS) - specific therapies 6 Clinically validated CNS - optimized Precision medicine enabling Conform
Slide 7: Business strategy and pipeline update
2. Business strategy and pipeline update
Slide 8: Business Strategy 2023: advancing vaccine and non-AD portfolio
NASDAQ: ACIU | AGM Presentation, June 2023 © 2023 AC Immune. Not to be used or reproduced without permission Business Strategy 2023: advancing vaccine and non - AD portfolio Focus on delivering Precision Medicine to enhance value creation Precision medicine Alzheimer’s disease Focused non - AD Parki
Slide 9: Broad and robust pipeline in neurodegenerative diseases
NASDAQ: ACIU | AGM Presentation, June 2023 © 2023 AC Immune. Not to be used or reproduced without permission Broad and robust pipeline in neurodegenerative diseases Driven by validated proprietary technology platforms for sustained growth 9 (1) Alzheimer’s disease; (2) Down syndrome - related Alzhei
Slide 10: Clinical-stage vaccine programs
3. Clinical - stage vaccine programs
Slide 11: Disruptive potential of SupraAntigen-V
NASDAQ: ACIU | AGM Presentation, June 2023 © 2023 AC Immune. Not to be used or reproduced without permission Disruptive potential of SupraAntigen ® - V Optimized vaccines delivering superior results in neurodegenerative diseases 11 (1) 100% response after 1 st injection; (2) Increases over time ■ Ro
Slide 12: SupraAntigen vaccines offer significant advantages over mAbs
NASDAQ: ACIU | AGM Presentation, June 2023 © 2023 AC Immune. Not to be used or reproduced without permission SupraAntigen ® vaccines offer significant advantages over mAbs 1 Vaccine – based approach provides opportunity to prevent neurodegenerative diseases globally SupraAntigen ® vaccines Monoclona
Slide 13: Pipeline focus: vaccines enabled by Precision Medicine
NASDAQ: ACIU | AGM Presentation, June 2023 © 2023 AC Immune. Not to be used or reproduced without permission (1) Neurodegenerative diseases ; (2) Alzheimer’s disease; (3) Down syndrome - related Alzheimer’s disease; (4) Alpha - synuclein; (5) Parkinson’s disease; (6) Optimized anti alpha - synuclein
Slide 14: ACI-24.060: Vaccine designed to clear Abeta plaques to treat AD
NASDAQ: ACIU | AGM Presentation, June 2023 © 2023 AC Immune. Not to be used or reproduced without permission ACI - 24.060: Vaccine designed to clear Abeta plaques to treat AD 1 ACI - 24.060 targets pyroGlu - and oligomeric Abeta, which are believed to drive AD progression 14 (1) Alzheimer’s disease;
Slide 15: ACI-24 program: Achievements and anticipated milestones
NASDAQ: ACIU | AGM Presentation, June 2023 © 2023 AC Immune. Not to be used or reproduced without permission ACI - 24 program: Achievements and anticipated milestones Initial Ph 1b/2 data on Abeta plaque reduction measured via PET 1 imaging expected in H1 2024 15 H1’24 Additional interim safety and
Slide 16: ACI-24.060: Potent immune response against toxic Abeta species
NASDAQ: ACIU | AGM Presentation, June 2023 © 2023 AC Immune. Not to be used or reproduced without permission ACI - 24.060: Potent immune response against toxic Abeta species Strong antibody response against targets of lecanemab and donanemab (NHP 1 ) (1) Non - human primates; (2) Pyroglutamate; (3)
Slide 17: Lowering of Amyloid PET burden is valid as a biomarker
NASDAQ: ACIU | AGM Presentation, June 2023 © 2023 AC Immune. Not to be used or reproduced without permission Lowering of Amyloid PET 1 burden is valid as a biomarker for clinical effect Lecanemab & donanemab trials established PET imaging as surrogate for clinical effect 17 ■ Targeting small aggrega
Slide 18: ACI-24 vaccination reduces Abeta plaque burden
NASDAQ: ACIU | AGM Presentation, June 2023 © 2023 AC Immune. Not to be used or reproduced without permission ACI - 24 vaccination reduces Abeta plaque burden Significant Abeta plaque reduction in vivo in preclinical APPxPS1 model 1 18 (1) Alzheimer’s disease mouse model: APPxPS - 1 double transgenic
Slide 19: Biomarker-based Phase 1b/2 study of ACI-24.060 in AD and DS
NASDAQ: ACIU | AGM Presentation, June 2023 © 2023 AC Immune. Not to be used or reproduced without permission Treatment in AD 4 (up to 4 dose/regimen cohorts) (12 months) 19 : Biomarker - based Phase 1b/2 study of ACI - 24.060 in AD 1 and DS 2 Placebo - controlled Phase 1b/2 Study Overview Trial Sche
Slide 20: ACI-7104: Anti-a-syn vaccine being developed for Parkinson's disease
NASDAQ: ACIU | AGM Presentation, June 2023 © 2023 AC Immune. Not to be used or reproduced without permission ACI - 7104: Anti - a - syn 1 vaccine being developed for Parkinson's disease Update on Phase 2 trial expected in H2 20 (1) alpha - synuclein; (2) Alzheimer’s disease; (3) Down syndrome - rela
Slide 21: Anti-a-syn vaccine is clinically validated in Parkinson's disease
NASDAQ: ACIU | AGM Presentation, June 2023 © 2023 AC Immune. Not to be used or reproduced without permission Anti - a - syn 1 vaccine is clinically validated 2 in Parkinson’s disease Phase 1 results in The Lancet Neurology support best - in - class profile 21 (1) alpha - synuclein; (2) Volc et al. ,
Slide 22: VACSYN: adaptive biomarker-based Phase 2 study in early PD
NASDAQ: ACIU | AGM Presentation, June 2023 © 2023 AC Immune. Not to be used or reproduced without permission 22 : : an adaptive biomarker - based Phase 2 study in early PD 1 Placebo - controlled Phase 2 Study Overview ▪ Key immunogenicity measures ▪ Measures of pathological a - syn 4 (a - syn oligom
Slide 23: ACI-35.030: Anti-pTau vaccine being developed for AD
NASDAQ: ACIU | AGM Presentation, June 2023 © 2023 AC Immune. Not to be used or reproduced without permission ACI - 35.030: Anti - pTau vaccine being developed for AD 1 Further clinical development in AD and milestone payment expected in H2 23 (1) Alzheimer’s disease; (2) Down syndrome - related Alzh
Slide 24: ACI-35.030 antibody titers versus JACI-35.054
NASDAQ: ACIU | AGM Presentation, June 2023 © 2023 AC Immune. Not to be used or reproduced without permission 0 8 16 24 32 40 48 56 64 72 10 3 10 4 10 5 Weeks A n t i b o d y T i t e r s ( G e o m e t r i c M e a n ) low dose JACI-35.054 mid dose ACI-35.030 0 8 16 24 32 40 48 56 64 72 10 2 10 3 10 4
Slide 25: Vaccines as a new class of treatment for neurodegenerative disease
NASDAQ: ACIU | AGM Presentation, June 2023 © 2023 AC Immune. Not to be used or reproduced without permission 25 Vaccines as a new class of treatment for neurodegenerative disease AC Immune vaccines: Potential for profound social and economic impact ■ Goal: Global vaccines for neurodegenerative disea
Slide 26: Achievements in 2022 and key milestones for 2023
4. Achievements in 2022 and key milestones for 2023
Slide 27: AC Immune 2022 highlights
NASDAQ: ACIU | AGM Presentation, June 2023 © 2023 AC Immune. Not to be used or reproduced without permission AC Immune 2022 highlights 27 Precision Medicine ▪ First ever live image of a - synuclein in a human brain ▪ New tracers for TDP - 43 and a - synuclein progressing towards clinical development
Slide 28: Key milestones for value creation in 2023
NASDAQ: ACIU | AGM Presentation, June 2023 © 2023 AC Immune. Not to be used or reproduced without permission Vaccines H1 H2 ACI - 24.060 Abeta Initiation of Down syndrome cohort of Phase 1b/2 ABATE study IND submission to enable expansion of ABATE study to U.S. Two interim analyses in AD 1 – safety,
Slide 29: Financial figures
5. Financial figures
Slide 30: Financial Overview
NASDAQ: ACIU | AGM Presentation, June 2023 © 2023 AC Immune. Not to be used or reproduced without permission 2022 Financial Overview 30 Key financial data (IFRS) For the year ended December 31, 2022 2021 Change (in CHF million except per share data) Revenues 3.9 - 3.9 R&D expenses (60.3) (62.3) 2.0
Slide 31: Summary and Strategic Outlook
6. Summary and Strategic Outlook
Slide 32: Today's strengths predict future success
NASDAQ: ACIU | AGM Presentation, June 2023 © 2023 AC Immune. Not to be used or reproduced without permission Today’s strengths predict future success Precision Medicine for mono - and combination therapy 32 (1) Neurodegenerative diseases Treating the right proteinopathy - in the right patient - at t
Slide 33: Shifting the treatment paradigm towards precision medicine and prevention
NASDAQ: ACIU | AGM Presentation, June 2023 © 2023 AC Immune. Not to be used or reproduced without permission 33 Shifting the treatment paradigm for neurodegenerative disease towards precision medicine and disease prevention AC Immune: Pioneering science and precision medicine
Slide 34: Agenda items and proposals of the Board of Directors
Agenda items and proposals of the Board of Directors
Slide 35: Approval of 2022 Financial Statements
NASDAQ: ACIU | AGM Presentation, June 2023 © 2023 AC Immune. Not to be used or reproduced without permission Agenda item 1 2022 IFRS Consolidated Financial Statements, 2022 Statutory Financial Statements and 2022 Compensation Report 35 1.1 Approval of 2022 IFRS Consolidated Financial Statements and
Slide 36: Advisory vote on the 2022 Compensation Report
NASDAQ: ACIU | AGM Presentation, June 2023 © 2023 AC Immune. Not to be used or reproduced without permission Agenda item 1 2022 IFRS Consolidated Financial Statements, 2022 Statutory Financial Statements and 2022 Compensation Report 36 1.2 Advisory vote on the 2022 Compensation Report ■ The Board of
Slide 37: Appropriation of Loss
NASDAQ: ACIU | AGM Presentation, June 2023 © 2023 AC Immune. Not to be used or reproduced without permission Agenda item 2 Appropriation of Loss 37 ■ The Board of Directors proposes the following appropriation: In CHF K Accumulated profit (loss) at Jan 1, 2022 (195,179) Net profit (loss) for the yea
Slide 38: Discharge of the Board of Directors and Executive Committee
NASDAQ: ACIU | AGM Presentation, June 2023 © 2023 AC Immune. Not to be used or reproduced without permission Agenda item 3 Discharge of the Board of Directors and of the Executive Committee 38 ■ The Board of Directors proposes that all members of the Board of Directors and of the Executive Committee
Slide 39: Compensation for the Board of Directors
NASDAQ: ACIU | AGM Presentation, June 2023 © 2023 AC Immune. Not to be used or reproduced without permission Agenda item 4 Compensation for the Members of the Board of Directors and the Executive Committee 39 4.1 Binding vote on Maximum Aggregate Compensation for Members of the Board of Directors fr
Slide 40: Compensation for the Executive Committee
NASDAQ: ACIU | AGM Presentation, June 2023 © 2023 AC Immune. Not to be used or reproduced without permission Agenda item 4 Compensation for the Members of the Board of Directors and the Executive Committee 40 4.2 Binding vote on Maximum Aggregate Compensation for Members of the Executive Committee f
Slide 41: Re-election of Members of the Board of Directors
NASDAQ: ACIU | AGM Presentation, June 2023 © 2023 AC Immune. Not to be used or reproduced without permission Agenda item 5 Election and re - elections 41 5.1 Re - election of Members of the Board of Directors ■ The Board of Directors proposes that each of the following persons be re - elected as dir
Slide 42: Election of Compensation, Nomination and Corporate Governance Committee
NASDAQ: ACIU | AGM Presentation, June 2023 © 2023 AC Immune. Not to be used or reproduced without permission Agenda item 5 Election and re - elections 42 5.2 Election and re - elections of Members of the Compensation, Nomination and Corporate Governance Committee ■ The Board of Directors proposes th
Slide 43: Re-election of the Statutory Auditors
NASDAQ: ACIU | AGM Presentation, June 2023 © 2023 AC Immune. Not to be used or reproduced without permission Agenda item 5 Election and re - elections 43 5.3 Re - election of the Statutory Auditors ■ The Board of Directors proposes that PricewaterhouseCoopers SA, in Pully, Switzerland, be re - elect
Slide 44: Re-election of the Independent Proxy
NASDAQ: ACIU | AGM Presentation, June 2023 © 2023 AC Immune. Not to be used or reproduced without permission Agenda item 5 Election and re - elections 44 5.4 Re - election of the Independent Proxy ■ The Board of Directors proposes that Reymond & Associés, Lausanne, which will be represented by any o
Slide 45: Changes in the Articles of Association
NASDAQ: ACIU | AGM Presentation, June 2023 © 2023 AC Immune. Not to be used or reproduced without permission Agenda item 6 Changes in the Articles of Association 45 ■ The Board of Directors is proposing to the Shareholders to accept certain changes to current Article 3b of the Company’s Articles of
Slide 46: Changes in the Articles of Association (continued)
NASDAQ: ACIU | AGM Presentation, June 2023 © 2023 AC Immune. Not to be used or reproduced without permission Agenda item 6 (continued) Changes in the Articles of Association 46 1 st Paragraph: “The share capital of the Company shall be increased by a maximum amount of CHF 100 , 000 through the issue
Slide 47: Changes in the Articles of Association (continued)
NASDAQ: ACIU | AGM Presentation, June 2023 © 2023 AC Immune. Not to be used or reproduced without permission Agenda item 6 (continued) Changes in the Articles of Association 47 2 nd Paragraph: “Shareholders' subscription rights are excluded . Shareholders' advance subscription rights with regard to
Slide 48: Changes in the Articles of Association (continued)
NASDAQ: ACIU | AGM Presentation, June 2023 © 2023 AC Immune. Not to be used or reproduced without permission Agenda item 6 (continued) Changes in the Articles of Association 48 3 rd Paragraph: “The exercise of conversion or option rights, as well as the waiver of such rights, may be exercised by wri
Slide 49: Thank you for your attendance and continued support
NASDAQ: ACIU | AGM Presentation, June 2023 © 2023 AC Immune. Not to be used or reproduced without permission 49 We thank y ou for your attendance and your continued support.